Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 48.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 117,963 shares of the biotechnology company’s stock after acquiring an additional 38,283 shares during the period. Nordea Investment Management AB’s holdings in Biogen were worth $17,901,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Biogen during the second quarter worth about $33,000. Ashton Thomas Securities LLC acquired a new stake in Biogen during the 3rd quarter worth approximately $33,000. Venturi Wealth Management LLC boosted its position in Biogen by 73.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 93 shares during the period. Versant Capital Management Inc grew its stake in shares of Biogen by 228.7% in the fourth quarter. Versant Capital Management Inc now owns 401 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 279 shares in the last quarter. Finally, FSA Wealth Management LLC purchased a new stake in shares of Biogen during the third quarter worth $74,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Trading Down 1.6 %

Shares of BIIB stock opened at $150.75 on Thursday. The company has a market capitalization of $21.97 billion, a P/E ratio of 13.62, a price-to-earnings-growth ratio of 1.74 and a beta of -0.07. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $158.35 and its two-hundred day moving average is $188.60. Biogen Inc. has a twelve month low of $145.07 and a twelve month high of $257.28.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.31. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.43 billion. Biogen had a net margin of 16.81% and a return on equity of 14.98%. Biogen’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period last year, the firm posted $4.36 EPS. Equities analysts forecast that Biogen Inc. will post 16.43 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BIIB. JPMorgan Chase & Co. decreased their target price on Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $300.00 price objective on shares of Biogen in a research report on Thursday, October 31st. StockNews.com cut shares of Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Stifel Nicolaus cut shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 price target for the company. in a report on Monday, December 16th. Finally, Needham & Company LLC lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $270.00 price objective on the stock. in a report on Monday, November 18th. Sixteen analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $232.40.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.